Made in North America: U.S. & Mexico-Based Capsule Manufacturing for Long-Term Supply Stability

Recent trade developments and domestic capacity shifts are changing the hard empty capsule sourcing landscape in the U.S. Final antidumping (AD) and countervailing duty (CVD) determinations now apply to hard empty capsules imported from China, India, Brazil, and Vietnam, cementing duties ranging from 8% to 88% for the next five years on top of existing, volatile tariff policies. In parallel, the announced closure of a major U.S. capsule manufacturing site by the end of 2026 will further reduce domestic capacity, reinforcing the need for proactive continuity planning.

Start a conversation

Current geopolitics and tariff policies increase landed cost volatility and supply chain planning complexity
Domestic manufacturing capacity for hard empty capsules is shifting with reduced U.S.-based supply options impacting overall supply/demand
Launch timelines in the nutraceutical industry make short-term, reactive supplier changes difficult and costly to manage
Broad scope of the case impacts capsule types used across human and animal health applications
Ongoing trade enforcement actions and global manufacturing volatility heighten supply chain risk

Imported capsule pricing is expected to normalize as unfair trade practices are addressed
Buyers are evaluating total cost of ownership rather than price alone
Supplier diversification and domestic sourcing are becoming strategic priorities
Long-term planning, continuity, and resilience are gaining importance over short-term cost advantages

Proactively qualifying North American - based capsule supply to reduce exposure to trade volatility and support long-term planning
Reassessing sourcing strategies based on landed cost, service, and regulatory alignment
Diversifying capsule suppliers geographically and domestically to reduce disruption risk
Building flexibility into inventory, forecasting, and production schedules

Onshore certainty: Capsules manufactured in Greenwood, South Carolina and Puebla, Mexico, with clear country of origin
Reduced trade exposure: Lower risk from tariffs, duties, and geopolitical disruption
Highest quality materials: Gelatin, HPMC, and pullulan capsule capabilities
Regulatory & quality alignment: U.S. regulatory standards with robust quality systems
Operational clarity: Forecast-based lead times, safety stock options, and continuity planning support
Scalable supply: Designed to support growth, product launches, and portfolio expansion

Safeguarding capsule supply chains

For nutraceutical manufacturers, these trade rulings elevate the importance of supply chain transparency and proactive planning. Understanding supplier exposure, maintaining open communication on pricing and lead-time impacts, and diversifying sourcing strategies are critical steps to mitigate disruption.

With AD/CVD orders expected to remain in effect for at least five years—and many trade cases extending well beyond initial terms—companies that prioritize domestic manufacturing and resilient supply partnerships are better positioned to protect continuity and manage future uncertainty.